| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Advances in Brief |
Departments of Medicine [R. A. G., J. D. M., R. N. D.], Cell and Developmental Biology [R. A. G., S. K. Dey., R. N. D.], Pediatrics [L. V. T., S. K. Das., S. K. Dey.], and Pharmacology [J. D. M.], Vanderbilt University School of Medicine, Nashville, Tennessee 37232
Inhibition of cyclooygenase-2 (COX-2) catalytic activity has proven successful in restricting the growth of epithelial-derived cancers in vivo. Whether COX-2 inhibitor therapy would be beneficial in the prevention and/or treatment of ovarian cancer, the most lethal gynecological malignancy worldwide, is not known. Most patients with ovarian cancer undergo cytoreductive therapy. Because many of the cytotoxic drugs used to treat ovarian cancer induce COX-2 expression, samples from patients that had not undergone cytoreductive therapy were specifically chosen for COX isoform expression analysis. A majority of specimens exhibited elevated levels of COX-1, not COX-2, mRNA, and protein compared with normal ovarian tissue. Focal regions within the tumor expressing high COX-1 also had elevated levels of pro-angiogenic proteins. Selective inhibition of COX-1, not COX-2, inhibited arachidonic acid-stimulated vascular endothelial growth factor production, which could be reversed by cotreatment with prostaglandin E2. Thus, COX-1 may contribute to carcinoma development in the ovary through stimulation of neovascularization. Clinical studies testing the efficacy of COX inhibition as adjuvant therapy for ovarian cancer may see more beneficial effects with adjuvant therapy with either a COX-1 selective or nonselective cyclooxygenase inhibitor as compared with a COX-2 selective drug.
This article has been cited by other articles:
|
|
 |
|
  R. S. Freedman, E. Wang, S. Voiculescu, R. Patenia, R. L. Bassett Jr., M. Deavers, F. M. Marincola, P. Yang, and R. A. Newman Comparative Analysis of Peritoneum and Tumor Eicosanoids and Pathways in Advanced Ovarian Cancer Clin. Cancer Res., October 1, 2007; 13(19): 5736 - 5744. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Daikoku, S. Tranguch, A. Chakrabarty, D. Wang, D. Khabele, S. Orsulic, J. D. Morrow, R. N. DuBois, and S. K. Dey Extracellular Signal-Regulated Kinase Is a Target of Cyclooxygenase-1-Peroxisome Proliferator-Activated Receptor-{delta} Signaling in Epithelial Ovarian Cancer Cancer Res., June 1, 2007; 67(11): 5285 - 5292. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W.-L. Yang, K. Q. Cai, J. L. Smedberg, E. R. Smith, A. Klein-Szanto, T. C. Hamilton, and X.-X. Xu A Reduction of Cyclooxygenase 2 Gene Dosage Counters the Ovarian Morphological Aging and Tumor Phenotype in Wv Mice Am. J. Pathol., April 1, 2007; 170(4): 1325 - 1336. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Battersby, K.J. Sales, A.R. Williams, R.A. Anderson, S. Gardner, and H.N. Jabbour Seminal plasma and prostaglandin E2 up-regulate fibroblast growth factor 2 expression in endometrial adenocarcinoma cells via E-series prostanoid-2 receptor-mediated transactivation of the epidermal growth factor receptor and extracellular signal-regulated kinase pathway Hum. Reprod., January 1, 2007; 22(1): 36 - 44. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Upadhyay, C. Liu, A. Chatterjee, M. O. Hoque, M. S. Kim, J. Engles, W. Westra, B. Trink, E. Ratovitski, and D. Sidransky LKB1/STK11 Suppresses Cyclooxygenase-2 Induction and Cellular Invasion through PEA3 in Lung Cancer Cancer Res., August 15, 2006; 66(16): 7870 - 7879. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Spinella, L. Rosano, S. Decandia, V. Di Castro, A. Albini, G. Elia, P. G. Natali, and A. Bagnato Antitumor Effect of Green Tea Polyphenol Epigallocatechin-3-Gallate in Ovarian Carcinoma Cells: Evidence for the Endothelin-1 as a Potential Target. Experimental Biology and Medicine, June 1, 2006; 231(6): 1123 - 1127. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Daikoku, S. Tranguch, I. N. Trofimova, D. M. Dinulescu, T. Jacks, A. Yu. Nikitin, D. C. Connolly, and S. K. Dey Cyclooxygenase-1 is overexpressed in multiple genetically engineered mouse models of epithelial ovarian cancer. Cancer Res., March 1, 2006; 66(5): 2527 - 2531. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. R. Holla, J. R. Mann, Q. Shi, and R. N. DuBois Prostaglandin E2 Regulates the Nuclear Receptor NR4A2 in Colorectal Cancer J. Biol. Chem., February 3, 2006; 281(5): 2676 - 2682. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Bagnato, F. Spinella, and L. Rosano Emerging role of the endothelin axis in ovarian tumor progression Endocr. Relat. Cancer, December 1, 2005; 12(4): 761 - 772. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Ates, O. Altundag, S. Aktolga, and K. Altundag Association between cyclooxygenase and epidermal growth factor receptor pathways in non-small cell lung cancer J. Thorac. Cardiovasc. Surg., November 1, 2005; 130(5): 1484 - 1485. [Full Text] [PDF]
|
|
|
|
|
|
B. H.A. von Rahden, H. J. Stein, F. Puhringer, I. Koch, R. Langer, G. Piontek, J. R. Siewert, H. Hofler, and M. Sarbia Coexpression of Cyclooxygenases (COX-1, COX-2) and Vascular Endothelial Growth Factors (VEGF-A, VEGF-C) in Esophageal Adenocarcinoma Cancer Res., June 15, 2005; 65(12): 5038 - 5044. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Daikoku, D. Wang, S. Tranguch, J. D. Morrow, S. Orsulic, R. N. DuBois, and S. K. Dey Cyclooxygenase-1 Is a Potential Target for Prevention and Treatment of Ovarian Epithelial Cancer Cancer Res., May 1, 2005; 65(9): 3735 - 3744. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Crist, Z. Zhang, M. You, W. T. Gunning, P. B. Conran, V. E. Steele, and R. A. Lubet Characterization of rat ovarian adenocarcinomas developed in response to direct instillation of 7,12-dimethylbenz[a]anthracene (DMBA) coated suture Carcinogenesis, May 1, 2005; 26(5): 951 - 957. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Brown and R. N. DuBois COX-2: A Molecular Target for Colorectal Cancer Prevention J. Clin. Oncol., April 20, 2005; 23(12): 2840 - 2855. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. R. Holla, D. Wang, J. R. Brown, J. R. Mann, S. Katkuri, and R. N. DuBois Prostaglandin E2 Regulates the Complement Inhibitor CD55/Decay-accelerating Factor in Colorectal Cancer J. Biol. Chem., January 7, 2005; 280(1): 476 - 483. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. T. Soumaoro, H. Uetake, T. Higuchi, Y. Takagi, M. Enomoto, and K. Sugihara Cyclooxygenase-2 Expression: A Significant Prognostic Indicator for Patients With Colorectal Cancer Clin. Cancer Res., December 15, 2004; 10(24): 8465 - 8471. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Spinella, L. Rosano, V. Di Castro, P. G. Natali, and A. Bagnato Endothelin-1-induced Prostaglandin E2-EP2, EP4 Signaling Regulates Vascular Endothelial Growth Factor Production and Ovarian Carcinoma Cell Invasion J. Biol. Chem., November 5, 2004; 279(45): 46700 - 46705. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Sirois, K. Sayasith, K. A. Brown, A. E. Stock, N. Bouchard, and M. Dore Cyclooxygenase-2 and its role in ovulation: a 2004 account Hum. Reprod. Update, September 1, 2004; 10(5): 373 - 385. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Spinella, L. Rosano, V. Di Castro, M. R. Nicotra, P. G. Natali, and A. Bagnato Inhibition of Cyclooxygenase-1 and -2 Expression by Targeting the Endothelin A Receptor in Human Ovarian Carcinoma Cells Clin. Cancer Res., July 15, 2004; 10(14): 4670 - 4679. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Quidville, N. Segond, E. Pidoux, R. Cohen, A. Jullienne, and S. Lausson Tumor Growth Inhibition by Indomethacin in a Mouse Model of Human Medullary Thyroid Cancer: Implication of Cyclooxygenases and 15-Hydroxyprostaglandin Dehydrogenase Endocrinology, May 1, 2004; 145(5): 2561 - 2571. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Wang, W.-g. Ma, L. Tejada, H. Zhang, J. D. Morrow, S. K. Das, and S. K. Dey Rescue of Female Infertility from the Loss of Cyclooxygenase-2 by Compensatory Up-regulation of Cyclooxygenase-1 Is a Function of Genetic Makeup J. Biol. Chem., March 12, 2004; 279(11): 10649 - 10658. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. G. Bottone Jr, J. M. Martinez, B. Alston-Mills, and T. E. Eling Gene modulation by Cox-1 and Cox-2 specific inhibitors in human colorectal carcinoma cancer cells Carcinogenesis, March 1, 2004; 25(3): 349 - 357. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Mulshine, J. C. Atkinson, R. O. Greer, V. A. Papadimitrakopoulou, C. Van Waes, S. Rudy, J. W. Martin, S. M. Steinberg, D. J. Liewehr, I. Avis, et al. Randomized, Double-Blind, Placebo-Controlled Phase IIB Trial of the Cyclooxygenase Inhibitor Ketorolac as an Oral Rinse in Oropharyngeal Leukoplakia Clin. Cancer Res., March 1, 2004; 10(5): 1565 - 1573. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T.-L. Erkinheimo, H. Lassus, P. Finne, B. P. van Rees, A. Leminen, O. Ylikorkala, C. Haglund, R. Butzow, and A. Ristimaki Elevated Cyclooxygenase-2 Expression Is Associated with Altered Expression of p53 and SMAD4, Amplification of HER-2/neu, and Poor Outcome in Serous Ovarian Carcinoma Clin. Cancer Res., January 15, 2004; 10(2): 538 - 545. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Raju and R. P. Bird Energy Restriction Reduces the Number of Advanced Aberrant Crypt Foci and Attenuates the Expression of Colonic Transforming Growth Factor {beta} and Cyclooxygenase Isoforms in Zucker Obese (fa/fa) Rats Cancer Res., October 15, 2003; 63(20): 6595 - 6601. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. G. Buchanan, D. Wang, F. Bargiacchi, and R. N. DuBois Prostaglandin E2 Regulates Cell Migration via the Intracellular Activation of the Epidermal Growth Factor Receptor J. Biol. Chem., September 12, 2003; 278(37): 35451 - 35457. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Cell Growth & Differentiation |
